Drugs / Tirzepatide
Tirzepatide
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | MOUNJARO | — | 2025-12-19 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | ZEPBOUND | — | 2024-10-18 – 2024-12-20 | fda.gov ↗ |
| Approved | EU (EMA) | Mounjaro | — | 2022-09-15 | europa.eu ↗ |
| Approved | US (FDA) | MOUNJARO | — | 2022-05-13 | fda.gov ↗ |
Trials 159 · started per year
today
US approved 2022
EU approved 2022
1
4
2
13
9
6
6
15
23
40
40
201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT07065552 | Apr 2026 → Jul 2028 expected | endometrial cancer, obesity disorder | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 0 | NCT06759701 | Jul 2025 → Dec 2026 expected | diabetes mellitus, prostate cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 0 | NCT06934642 | Jun 2025 → Aug 2026 overdue | metabolic dysfunction-associated steatotic liver disease, obesity disorder | University of New Mexico | Recruiting | No outcome recorded |
| Phase 0 | NCT06734273 | Mar 2025 → Sep 2027 expected | obesity disorder | Nicholas Skertich | Recruiting | No outcome recorded |
| Phase 0 | NCT06751589 | Dec 2024 → Dec 2027 expected | endometrial cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 125 trials | ||||||
| Phase 1 | NCT07095517 | Feb 2026 → Mar 2027 expected | colorectal adenoma, colorectal cancer | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT07299084 | Jan → Nov 2026 expected | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06916065 | Apr 2025 → Jan 2026 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06890611 | Mar → Sep 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06648031 | Dec 2024 → Jul 2025 | type 2 diabetes mellitus | Lexaria Bioscience Corp. | Completed | No outcome recorded |
| Phase 1 | NCT06575738 | Oct 2024 → Sep 2027 expected | obesity disorder | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT06297616 | Apr 2024 → Nov 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05978713 | Jul 2023 → Mar 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05810597 | Apr → Jul 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05696847 | Feb 2023 → Jan 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04235959 | Oct 2020 → Aug 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04407234 | Sep 2020 → Jan 2021 | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04311411 | Aug 2020 → Dec 2022 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04311424 | Jul → Oct 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04081337 | Jul 2020 → May 2022 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04172987 | Feb 2020 → Feb 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04050553 | Feb 2020 → Jan 2022 | hypoglycemia, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04050670 | Sep 2019 → Apr 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04004988 | Aug → Dec 2019 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03940742 | Jul 2019 → Sep 2020 | liver disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03951753 | Jun 2019 → Apr 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03482024 | Mar 2018 → Aug 2019 | end stage renal failure, impaired renal function disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03375463 | Dec 2017 → Dec 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03322631 | Nov 2017 → May 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02759107 | May 2016 → Jun 2017 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07463846 | Mar 2026 → Apr 2027 expected | obesity disorder | Alnylam Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05751720 | Oct 2023 → Oct 2024 | NAFLD1, metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | Dr Adnan Agha | Unknown | No outcome recorded |
| Phase 245 trials | ||||||
| Phase 2 | NCT06180616 | Dec 2026 → Dec 2028 expected | type 1 diabetes mellitus | Royal North Shore Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07468552 | Nov 2026 → Mar 2028 expected | cannabis dependence | National Institute on Drug Abuse (NIDA) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07693608 | Aug 2026 → Feb 2030 expected | cocaine dependence, methamphetamine dependence, obesity disorder | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07078838 | Aug 2026 → Mar 2029 expected | endometrial cancer, endometrial endometrioid adenocarcinoma, intraepithelial neoplasia | UNC Lineberger Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07349641 | Jul 2026 → Dec 2028 expected | atypical endometrial hyperplasia, endometrial endometrioid adenocarcinoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06820281 | Jul 2026 → Dec 2027 expected | type 1 diabetes mellitus | Victor Chang Cardiac Research Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07265752 | Jul 2026 → Jun 2028 expected | cannabis dependence | Brigham and Women's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07602699 | Jun 2026 → Mar 2028 expected | — | University of Southern California | Recruiting | No outcome recorded |
| Phase 2 | NCT07605247 | Jun 2026 → Jan 2028 expected | endometrial cancer | Rutgers, The State University of New Jersey | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07527910 | May 2026 → Mar 2030 expected | metabolic dysfunction-associated steatotic liver disease | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT07179120 | May → Aug 2026 overdue | male infertility | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07228741 | Apr 2026 → Nov 2027 expected | childhood acute lymphoblastic leukemia, obesity disorder | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07107334 | Apr 2026 → Nov 2028 expected | endometrial endometrioid adenocarcinoma | University of Florida | Recruiting | No outcome recorded |
| Phase 2 | NCT06811324 | Apr 2026 → Apr 2027 expected | pelvic muscle wasting | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 2 | NCT06651177 | Jan 2026 → Sep 2027 expected | opiate dependence | T. John Winhusen, PhD | Recruiting | No outcome recorded |
| Phase 2 | NCT07202247 | Jan 2026 → Apr 2028 expected | prostate carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07292519 | Jan 2026 → May 2027 expected | alcohol-related disorders, obesity disorder | South West Sydney Local Health District | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06935838 | Nov 2025 → Jun 2026 | HIV infectious disease, obesity disorder | University of Hawaii | Completed | No outcome recorded |
| Phase 2 | NCT05933499 | Nov 2025 → Dec 2028 expected | obesity disorder | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06994338 | Oct 2025 → Aug 2026 overdue | alcohol-related disorders, obesity disorder | University of Southern California | Recruiting | No outcome recorded |
| Phase 2 | NCT06847399 | Sep 2025 → Dec 2027 expected | binge eating disorder, obesity disorder | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2 | NCT06727331 | Sep 2025 → Mar 2027 expected | alcohol-related disorders | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07091734 | Sep 2025 → Sep 2029 expected | partial lipodystrophy | University of Michigan | Recruiting | No outcome recorded |
| Phase 2 | NCT06073184 | Aug 2025 → Feb 2027 expected | atypical endometrial hyperplasia, endometrial cancer | University Health Network, Toronto | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06901349 | May → Jun 2025 | obesity disorder | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 2 | NCT06976853 | May 2025 → May 2028 expected | Crohn disease | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06939088 | May 2025 → Aug 2028 expected | alcohol dependence, schizophrenia | Anders Fink-Jensen, MD, DMSci | Recruiting | No outcome recorded |
| Phase 2 | NCT06802081 | Apr 2025 → Dec 2026 expected | atrial fibrillation, obesity disorder | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT06893211 | Mar → Nov 2025 | obesity disorder | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 2 | NCT06582875 | Mar 2025 → Jun 2029 expected | autosomal dominant polycystic kidney disease, obesity disorder | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2 | NCT06745128 | Feb 2025 → Mar 2026 overdue | methamphetamine dependence, obesity disorder | University of Texas Southwestern Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06517212 | Nov 2024 → Aug 2029 expected | breast cancer | Baylor Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06518837 | Oct 2024 → Sep 2027 expected | hormone receptor-positive breast cancer | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT06643728 | Oct 2024 → Jan 2026 overdue | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06603571 | Sep 2024 → Jul 2026 overdue | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06515418 | Jun 2024 → Feb 2025 | obesity disorder | BioAge Labs, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT06373146 | Apr 2024 → Dec 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT05659368 | Jan → Oct 2024 | Wolfram syndrome 1 | Ospedale San Raffaele | Unknown | No outcome recorded |
| Phase 2 | NCT06143956 | Nov 2023 → Sep 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT05912621 | Nov 2023 → Jun 2028 expected | morbid obesity | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT06037252 | Sep 2023 → Jan 2026 overdue | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05536804 | Feb 2023 → Sep 2026 expected | chronic kidney disease, obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04166773 | Nov 2019 → Dec 2023 | metabolic dysfunction-associated steatohepatitis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT03311724 | Oct 2017 → Apr 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT03131687 | May 2017 → Aug 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07284511 | May 2026 → Jan 2028 expected | type 1 diabetes mellitus | McGill University Health Centre/Research Institute of the McGill University Health Centre | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07223242 | Feb 2025 → Dec 2026 expected | cardiomyopathy, heart failure | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06162715 | Oct 2024 → Jan 2027 expected | morbid obesity | Vanderbilt University Medical Center | Enrolling by invitation | No outcome recorded |
| Phase 340 trials | ||||||
| Phase 3 | NCT07671248 | Aug 2026 → Jul 2028 expected | cannabis dependence | McMaster University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07635953 | Jul 2026 → Jul 2029 expected | diabetes mellitus | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07481747 | Feb 2026 → Feb 2027 expected | obesity disorder | Hudson Biotech | Recruiting | No outcome recorded |
| Phase 3 | NCT07165028 | Oct 2025 → Aug 2030 expected | metabolic dysfunction-associated steatotic liver disease | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06937099 | Jun 2025 → May 2028 expected | Crohn disease, obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06937086 | Jun 2025 → Apr 2028 expected | obesity disorder, ulcerative colitis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06962280 | May 2025 → Nov 2026 expected | obesity disorder, type 1 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06914895 | Apr 2025 → Nov 2026 expected | obesity disorder, type 1 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06630585 | Feb 2025 → Jun 2026 overdue | type 1 diabetes mellitus | University of Bern | Recruiting | No outcome recorded |
| Phase 3 | NCT06918405 | Jan 2025 → Jun 2026 overdue | obesity disorder | Chittagong Medical College | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06246799 | Nov 2024 → Apr 2029 expected | type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 3 | NCT06534411 | Nov 2024 → Jun 2026 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06588283 | Sep 2024 → Jan 2026 | obesity disorder, psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT06588296 | Sep 2024 → Nov 2025 | obesity disorder, psoriatic arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT06439277 | Jun 2024 → Oct 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06075667 | Oct 2023 → Jun 2026 overdue | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06047548 | Sep 2023 → Jan 2026 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05963022 | Aug 2023 → Oct 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05822830 | Apr 2023 → Nov 2024 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05691712 | Feb 2023 → Jul 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05556512 | Oct 2022 → Oct 2027 expected | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05412004 | Jun 2022 → Mar 2024 | obesity disorder, obstructive sleep apnea syndrome | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05260021 | Apr 2022 → Jul 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05024032 | Sep 2021 → Dec 2022 | metabolic disease, obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04844918 | May 2021 → Jun 2023 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04847557 | Apr 2021 → Jul 2024 | diastolic heart failure, obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04657003 | Mar 2021 → Mar 2023 | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04660643 | Mar 2021 → Apr 2023 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04657016 | Mar 2021 → Apr 2023 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04537923 | Oct 2020 → Oct 2022 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04255433 | May 2020 → Jun 2025 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04093752 | Dec 2019 → Nov 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04184622 | Dec 2019 → Apr 2022 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04039503 | Aug 2019 → Dec 2020 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03987919 | Jul 2019 → Jan 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03954834 | Jun 2019 → Oct 2020 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03861052 | May 2019 → Mar 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03882970 | Apr 2019 → Dec 2020 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03861039 | Mar 2019 → Jan 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03730662 | Nov 2018 → Jan 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 430 trials | ||||||
| Phase 4 | NCT07027969 | Nov 2026 → Dec 2029 expected | atrial fibrillation, obesity disorder | Ali Aminian | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07630454 | Aug 2026 → Aug 2029 expected | atrial fibrillation, diastolic heart failure | Yunlong Wang | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07588438 | Jul 2026 → Aug 2027 expected | obesity disorder, type 2 diabetes mellitus | Las Rías Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT07706088 | Jul 2026 → Jul 2028 expected | diabetes mellitus, neuropathy, small fiber | Post Graduate Institute of Medical Education and Research, Chandigarh | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07707778 | Jun 2026 → Dec 2027 expected | HIV infectious disease, diabetes mellitus, hyperlipidemia, metabolic dysfunction-associated steatotic liver disease +2 | National Taiwan University Clinical Trial Center | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07257484 | Jun 2026 → Dec 2027 expected | breast cancer, obesity disorder | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 4 | NCT07554638 | Jun 2026 → Apr 2029 expected | diastolic heart failure, obesity disorder | Columbia University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07218445 | Apr 2026 → Sep 2027 expected | obesity disorder, premature menopause | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT07483801 | Mar 2026 → Apr 2027 expected | cardiovascular disorder | Cambridge University Hospitals NHS Foundation Trust | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07438444 | Feb 2026 → Oct 2027 expected | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 4 | NCT07423247 | Jan → Jul 2026 overdue | — | Shahid Beheshti University of Medical Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT07247084 | Nov 2025 → Jul 2029 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 4 | NCT07154719 | Oct 2025 → Feb 2027 expected | obesity disorder, osteoporosis | Pennington Biomedical Research Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06801015 | Oct 2025 → Jan 2028 expected | obesity disorder | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07096908 | Jul 2025 → Feb 2028 expected | obesity disorder, type 1 diabetes mellitus | Dasman Diabetes Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT06861439 | Jul 2025 → Sep 2026 expected | obesity disorder | Wake Forest University Health Sciences | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07057310 | May 2025 → Dec 2026 expected | obesity disorder | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06721507 | Mar 2025 → Dec 2026 expected | obesity disorder | Marlene Starr | Recruiting | No outcome recorded |
| Phase 4 | NCT06857942 | Mar 2025 → May 2028 expected | obesity disorder, psoriasis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 4 | NCT06864026 | Mar 2025 → Nov 2027 expected | obesity disorder, psoriatic arthritis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 4 | NCT06774079 | Mar 2025 → Mar 2027 expected | Crohn disease | University of Miami | Recruiting | No outcome recorded |
| Phase 4 | NCT06657209 | Jan 2025 → Dec 2027 expected | prediabetes syndrome, type 2 diabetes mellitus | Stanford University | Recruiting | No outcome recorded |
| Phase 4 | NCT06191848 | Nov 2024 → May 2027 expected | obesity disorder, osteoarthritis, knee | University of Melbourne | Recruiting | No outcome recorded |
| Phase 4 | NCT06635057 | Oct 2024 → Apr 2026 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT06606821 | Oct 2024 → Mar 2027 expected | atherosclerotic cardiovascular disease, coronary artery disorder, coronary microvascular disorder, obesity disorder | Tina Vilsbøll | Recruiting | No outcome recorded |
| Phase 4 | NCT06009653 | Sep 2023 → May 2024 | metabolic disease, obesity disorder | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 4 | NCT05706506 | Mar → Oct 2023 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT05564039 | Nov 2022 → Jul 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT05433584 | Aug 2022 → Oct 2025 overdue | type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05553093 | Mar 2022 → Dec 2023 overdue | type 2 diabetes mellitus | Nanjing First Hospital, Nanjing Medical University | Recruiting | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT07633639 | May 2026 → May 2028 expected | obesity disorder | China-Japan Friendship Hospital | Recruiting | No outcome recorded |
| — | NCT07176663 | Feb → Apr 2026 overdue | obesity disorder | Shahid Beheshti University of Medical Sciences | Not yet recruiting | No outcome recorded |
| — | NCT07373834 | Jan → Dec 2026 expected | obesity disorder | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| — | NCT07364175 | Jan 2026 → Jan 2027 expected | hypertensive disorder, obesity disorder | Cambridge University Hospitals NHS Foundation Trust | Recruiting | No outcome recorded |
| — | NCT07319975 | Dec 2025 → Oct 2026 expected | obesity disorder | Istanbul Galata University | Not yet recruiting | No outcome recorded |
| — | NCT07293325 | Jun 2025 → Apr 2027 expected | obesity disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| — | NCT07303556 | Dec 2024 → Jul 2025 overdue | heart failure, hypertensive disorder, type 2 diabetes mellitus | Nazarbayev University | Active not recruiting | No outcome recorded |
| — | NCT07368855 | May 2024 → Jul 2025 | depressive disorder, obesity disorder | University of California, San Diego | Completed | No outcome recorded |
| — | NCT06301256 | Mar 2024 → Mar 2025 | hidradenitis suppurativa | Florida Academic Centers Research and Education, LLC | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 43 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07559500 Comparator | May 2026 → Dec 2031 expected | alcohol-related disorders | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Recruiting | No outcome recorded |
| Phase 1 | NCT06345066 Background | Apr 2024 → Sep 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05822544 Background | Apr 2023 → Feb 2026 overdue | obesity disorder, type 2 diabetes mellitus | OrsoBio, Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT05582096 Background | Nov 2022 → Jun 2023 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07245771 Background | Nov 2025 → Feb 2027 expected | obesity disorder | Ikaria Bioscience Pty Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07000955 Comparator | Jun 2025 → Sep 2026 expected | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06700538 Background | Dec 2024 → Sep 2027 expected | obesity disorder | Arrowhead Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT06732245 Comparator | Aug 2026 → Aug 2027 expected | obesity disorder | Biomed Industries, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07676331 Comparator | Aug 2026 → Mar 2028 expected | female breast carcinoma, hormone receptor-positive breast cancer | Universitaire Ziekenhuizen KU Leuven | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07671391 Background | Aug 2026 → Jul 2027 expected | — | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07573163 Comparator | Jul 2026 → Jul 2028 expected | ACTH-independent Cushing syndrome | Alaa Sada | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07046819 Comparator | Jun → Jul 2026 overdue | alcohol-related disorders, metabolic dysfunction and alcohol associated liver disease | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Recruiting | No outcome recorded |
| Phase 2 | NCT07521631 Comparator | Mar 2026 → Feb 2027 expected | obesity disorder | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07220473 Comparator | Feb 2026 → Nov 2027 expected | — | The University of Texas Medical Branch, Galveston | Recruiting | No outcome recorded |
| Phase 2 | NCT07128082 Comparator | Oct 2025 → Dec 2026 expected | long COVID-19 | Scripps Translational Science Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06965413 Background | May 2025 → Aug 2026 overdue | obesity disorder | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06911203 Comparator | Apr 2025 → Jan 2026 overdue | obesity disorder | BrightGene Bio-Medical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06737042 Comparator | Feb 2025 → Feb 2026 | obesity disorder | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
| Phase 2 | NCT06565611 Comparator | Aug 2024 → Feb 2025 overdue | obesity disorder | Palatin Technologies, Inc | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06445075 Background | May 2024 → Mar 2025 | — | Scholar Rock, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06326060 Comparator | Mar 2024 → Apr 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT06326047 Comparator | Mar 2024 → Sep 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07298915 Background | Aug → Dec 2026 expected | obesity disorder | University of Virginia | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06662383 Comparator | Nov 2024 → Nov 2026 expected | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06221969 Comparator | Jan 2024 → Mar 2026 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06131437 Comparator | Nov 2023 → Dec 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT07697391 Comparator | Jul 2026 → Oct 2027 expected | obesity disorder, type 2 diabetes mellitus | The First Affiliated Hospital of Anhui Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07555730 Comparator | Apr 2026 → Sep 2028 expected | type 2 diabetes mellitus | Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07191873 Comparator | Feb 2026 → Feb 2027 expected | pseudotumor cerebri | Duke University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07354880 Comparator | Jan 2026 → Jun 2027 expected | congenital heart disease, obesity disorder | University Medical Centre Ljubljana | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07058155 Comparator | Dec 2025 → Feb 2029 expected | cirrhosis of liver, morbid obesity, portal hypertension | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT07326111 Comparator | Dec 2025 → Dec 2028 expected | obesity disorder, polycystic ovary syndrome | University of Bonn | Recruiting | No outcome recorded |
| Phase 4 | NCT06901245 Comparator | May 2025 → Jun 2026 overdue | Prader-Willi syndrome, acquired hypothalamic obesity | Grace Kim | Recruiting | No outcome recorded |
| Phase 4 | NCT06803888 Comparator | Jan 2025 → Jul 2027 expected | obesity disorder | Ali Aminian | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06533527 Comparator | Jul 2024 → May 2025 | gastroparesis, obesity disorder, type 2 diabetes mellitus | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT06374875 Comparator | Jul 2024 → May 2029 expected | NAFLD1, fibrotic liver disease, metabolic dysfunction-associated steatohepatitis, obesity disorder | Ali Aminian | Recruiting | No outcome recorded |
| Phase 4 | NCT05708859 Comparator | Jan 2024 → Dec 2025 overdue | atherosclerosis, type 2 diabetes mellitus | Matthew J. Budoff | Recruiting | No outcome recorded |
| Phase 4 | NCT05812183 Background | Jul 2023 → Feb 2025 | — | University of California, Los Angeles | Withdrawn | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07382024 Comparator | Jun 2026 → Dec 2027 expected | obesity disorder, persistent atrial fibrillation | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07574723 Comparator | May 2026 → May 2029 expected | obesity disorder | Dasman Diabetes Institute | Recruiting | No outcome recorded |
| — | NCT07589322 Comparator | Mar 2026 → Sep 2028 expected | abdominal obesity-metabolic syndrome | Tri-Service General Hospital (TSGH) | Recruiting | No outcome recorded |
| — | NCT07443956 Comparator | Mar 2026 → Feb 2028 expected | obesity disorder, psoriatic arthritis | NHS Greater Glasgow and Clyde | Recruiting | No outcome recorded |
| — | NCT05990374 Comparator | Aug 2023 → Jan 2024 | type 2 diabetes mellitus | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-06 | Novo Nordisk A/S | People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data novonordisk.com ↗ |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 205 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tirzepatide | “Subjects will receive a glucagon-like peptide 1 receptor agonist (either semaglutide, tirzepatide or liraglutide) by self-injection or orally (semaglutide or orforglipron) for...” NCT07107334 ↗200“Tirzepatide (Mounjaro), a drug developed for the treatment of type 2 diabetes, is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 that has been...” NCT07354880 ↗ “Three incretin-based medications that have been approved for treatment of obesity including liraglutide, semaglutide, or tirzepatide will be used in the nonsurgical group.” NCT06374875 ↗ “Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life?” NCT07368855 ↗ “Agents may include incretin-based therapies (e.g., Semaglutide, Tirzepatide) or other FDA-approved AOMs such as Topiramate or Phentermine.” NCT07058155 ↗ “The choice of AOMs considered may include metformin, topiramate, liraglutide, dulaglutide, semaglutide, tirzepatide, and empagliflozin.” NCT07027969 ↗ “In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery.” NCT06734273 ↗ “Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner.” NCT06326047 ↗ “Initiation/intensification of weight loss medications, such as semaglutide or tirzepatide” NCT07223242 ↗ “The group will receive GLP-1 analogues (subcutaneous Tirzepatide).” NCT05751720 ↗ “Tirzepatide, empagliflozin, and pioglitazone treatment.” NCT07635953 ↗ “Tirzepatide (Zepbound)” NCT05812183 ↗ “Tirzepatide” NCT06073184 ↗ “Tirzepatide” NCT06533527 ↗ |
| Known as | BG-121 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297839 ↗ |
| Known as | LIPOLESS | “Participants will receive subcutaneous injections of tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.) once weekly.” NCT07588438 ↗ |
| Known as | LY3298176 | “A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both” NCT05260021 ↗3“A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities” NCT06075667 ↗ “A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity” NCT06037252 ↗ “LY3298176” NCT04311411 ↗ |
| Known as | Mounjaro | “Tirzepatide (Mounjaro), a drug developed for the treatment of type 2 diabetes, is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 that has been...” NCT07354880 ↗5“We will use commercially available tirzepatide, primarily dispensed as ZEPBOUND® for this study, but in the event of medication shortage or other pharmacy-related issue,...” NCT06745128 ↗ “If possible, patients will be placed on high-dose tirzepatide (Mounjaro or Zepbound 15 mg once weekly injection) or high-dose semaglutide (Wegovy 2.4 mg once weekly injection...” NCT06374875 ↗ “New medicines called GLP-1 receptor agonists, like semaglutide (Ozempic) and tirzepatide (Mounjaro), help people lose weight and improve health.” NCT07179120 ↗ “Tirzepatide (s.c. weekly), a Glucagon-like peptide-1 (GLP-1) receptor agonist • Other Names: * Mounjaro * Zepbound” NCT06732245 ↗ “Tirzepatide (Mounjaro)” NCT07303556 ↗ |
| Known as | Mounjaro (autoinjector) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297839 ↗ |
| Known as | Munjaro | “the effects of the anti-obesity drug tirzepatide (Munjaro) on cardiovascular and metabolic factors in obese patients with ACHD.” NCT07354880 ↗ |
| Known as | Spartina | “weekly injection of Tirzepatide (Spartina)” NCT07176663 ↗ |
| Known as | Tirzepatida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297839 ↗ |
| Known as | TZP | “This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D).” NCT06820281 ↗ |
| Known as | Zepbound | “We will use commercially available tirzepatide, primarily dispensed as ZEPBOUND® for this study, but in the event of medication shortage or other pharmacy-related issue,...” NCT06745128 ↗6“If possible, patients will be placed on high-dose tirzepatide (Mounjaro or Zepbound 15 mg once weekly injection) or high-dose semaglutide (Wegovy 2.4 mg once weekly injection...” NCT06374875 ↗ “injectable medication called tirzepatide (Zepbound) glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP-GLP-1 RA) medication” NCT06774079 ↗ “The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID.” NCT07128082 ↗ “Tirzepatide (s.c. weekly), a Glucagon-like peptide-1 (GLP-1) receptor agonist • Other Names: * Mounjaro * Zepbound” NCT06732245 ↗ “Tirzepatide (Zepbound)” NCT05812183 ↗ |
| Known as | Zepbound (autoinjector) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297839 ↗ |
| Action | Activate | “Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist” PMID 35210595 ↗ Feb 20222“Gastric inhibitory polypeptide receptor agonist” CHEMBL4297839 ↗ “Glucagon-like peptide 1 receptor agonist” CHEMBL4297839 ↗ |
| Modality | Peptide | “Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist used for the treatment of type 2 diabetes.” PMID 37786396 ↗ Nov 2023 |
| Route | Subcutaneous | “Administered SC” NCT03131687 ↗ |
| Target | GIPR | “Gastric inhibitory polypeptide receptor agonist” CHEMBL4297839 ↗ |
| Target | GLP1R | “Glucagon-like peptide 1 receptor agonist” CHEMBL4297839 ↗ |